Protein Glycosylation: "New-yet-Old" Target for Immunotherapy.

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

The use of checkpoint monotherapy in treating cancer has limited success. Post-translational modifications (PTM) of proteins such as glycosylation might have clinical implications due to distinct modifications found in diseases and its regulatory role in the immunometabolic gene expression. Such novel mechanistic targets hold great promise for combined immunotherapy.See related article by Shi et al., p. 5990.

Keyphrases

gene expression
papillary thyroid
dna damage
dna methylation
squamous cell
cell cycle
transcription factor
combination therapy
big data
protein protein
open label
randomized controlled trial
amino acid
childhood cancer
lymph node metastasis
clinical trial
small molecule
oxidative stress